A new study in Annals of Internal Medicine suggests that one in five COVID patients who take nirmatrelvir/ritonavir (Paxlovid) may experience viral rebound, a far higher proportion than seen in prior analyses.
In this video, study author Mark Siedner, MD, MPH, of Harvard Medical School in Boston, discusses the research and how it may inform best use of the antiviral.
4 окт 2024